Podcasts about losing battle

Episode 448... More new bangers from the BGP you can't deny. One from our upcoming release in April and a new one from our collaboration with the El Matador (Chico punk legend)! Also new stuff sent in by Columbia's Deshumanizer and Brazil's two-piece D-Beat ripper band Odiär!! A bunch of other new ones and some we've been dying to get to for a while. As promised, here's the elastic and tupperware jam video (fountanemusic) we mention at the end of the show. Enjoy!Listen to Episode 448: (scroll for set list)On ARCHIVE.On Apple or Google Podcasts, hit "play."On blogspot, play it below:Listen to The Brothers Grim Punkcast:ARCHIVE.Org - hear/download past episodesPUNK ROCK DEMONSTRATION - Wednesdays 7 p.m. PSTRIPPER RADIO - Fridays & Saturdays 7 p.m. PSTApple PodcastsGoogle PodcastsYouTube PodcastsContact Brothers Grim Punk:brothersgrimpunk@gmail.com - In a punk band? Send us your music! Want us to make you a punk song? Email us some lyrics!@Punkbot138 on Instagram@BrosGrimPunk on XMore Punk Music:Bandcamp - Follow us and download our albums: Brothers Grim Punk, Fight Music, and more!YouTube - tons of punk playlists, from Anarchy to Zombies!DesPunkAnizar...Less Than 1%    1:22  Brothers Grim Punk Unreleased 2024 Single SF For the Better 0:54 VVM Demo 2023 Mind Games 1:04 common enemy As the World Burns Drinking with WWF Superstars 2:21 El Matador and The BGP  Unreleased 2024 Single Goodbye California (bkgrd) 2:24 The Queers Grow Up Punk Columbia  Enemigxs 2:36 Deshumanizar  2024 Demo Death Drug Psychosis 1:02 Green Beret "Hardcore 2014" - West Coast Tour Tape FIGHT BACK 0:53 BALLISTIC AX DMU-001: BALLISTIC AX - BALLISTIC ACTS OF TERROR Out On The Street 1:26 LAUGHING BOY - Demo 2016 Keep In Step 1:13 WATCHDOG - Demo Authority Abuse 1:06 POLICY OF TRUTH - Demo I'd Rather Die Than Be In Your Cover Band 1:40 Shut The Fuck Up Enter the Blue Room Love Me, I'm A Liberal (bkgrd) 4:02 Jello Biafra & Mojo Nixon Pairie Home Invasion Brazil a la mierda nazi_fuck nazi  1:05  Odiär- Mortos não acabarão  BREAK OR BE BROKE 1:42 DMU-014: STREET HASSLE - WINTER 2024 PROMO Philly HEX 1:00 SHARE GOD's FAVORITE ep Toronto Barbed Wire Disease 2:28 BRAIN ITCH The Future Burns Phoenix WARSYSTEM (Shitlickers) 0:40 D-ABSENT coupla covers WA BOOK OF THE MACHINES 1:06 SPIRAL DEMISE DEMO So Cal one 1:11 FAST 6 fast ones Unite And Fight (To Smash the Right) (bkgrd) 5:07 S.I.N. PUNX It's What Unites Us vol 6 Austin TX PRICE OF PROGRESS 1:07 Scorched Earth Demo 2022 Austin SPEEDFUCKINGNOISEATTACK 7:42 EMPART SPEEDFUCKINGNOISEATTACK Austin Hooked Jaw 1:11 Impalers LP Belgium GG Is A Bootleg 0:59 Freddie & The Vangrails album #2 teaser... Belgium HATE SONG 1:02 Shredder DEMO Die World Die 1:51 Ill Content Cheap Ass Music Vol.1 Guana Batz - (bkgrd) Piledriver Boogie Losing Battle 0:44 Corrective Measure S/T 7" Quarantine Me 1:00 BLOCKHEAD - Demo COME CORRECT 1:19 ULTRAS ULTRAS DENY - The Harder You Fall 1:42 Sound of chaos records NO CLASS FOR HELL CRUST SOUND vol 3. Dögölj Meg! (Die!) 1:50 Lecsa - Punk Legális Pusztítás (Legal Destruction) Mexican Slum Rats (bkgrd)Germany No Gods,No Masters, No Leaders 1:38 Kläpträp Dipsomania for Conquest

What is the point of the Waitangi Tribunal if it doesn't have the power to stop a government that appears to be acting against the interests of Māori? 

Fighting a losing battle

Lon and Derek discuss where things stand with the Chicago Bears and Justin Fields, as more reports point to the Bears drafting a QB with the first pick as things stand today. Later, the guys take a look at the juicy college basketball slate on Saturday.

Last year, I made a $10 mistake on my personal tax return that resulted in the IRS demanding $175 in penalties. Although it's cheaper and probably smarter to send them a check, I just couldn't let it go. Especially since according to the tax code, I don't owe any penalties.   When I experience an injustice, ... The post Fighting a Losing Battle appeared first on Unconventional Business Network.

A roll of the eye, an uncomfortable laugh or a deep sigh might be all more subtle flavors of control, yet they are still ways to diminish what someone else says or thinks.This week, I am taking a look at a topic that might hit a bit close to home for some of us (take a listen to see how close to my home it actually hit) - Ep 137: The Losing Battle of Power & Control in Marriage.Here's what you'll discover:What's behind the battle: Ever wonder why we fight for control and power in our relationships? I'll uncover the hidden drivers behind this age-old struggle.Ways we attempt to control: From subtle tactics to overt actions, I'll explore the various strategies we employ to assert control, shedding light on behaviors you might not even realize you are engaging in.The path to change: It's not about changing your partner; it's about transforming yourself. I'll share practical steps to relinquish control, fostering a more intimate, connected relationship.Relationships can be tricky, and control and power battles are more common than we think. But guess what? Change is possible, and it starts with self-awareness and self-compassion.Listen now on the AwakenYou in Your Marriage podcast to discover how to break free from these patterns and nurture a love that's built on trust, understanding, and authenticity. Remember, change takes time, and it's okay to stumble along the way. Be patient with yourself and your partner as you embark on this transformative journey. Ready to break free from the losing battle of control? Tune in and let's awaken your relationship together! CBS News Interview: 6 Tips For A Healthy & Loving RelationshipDownload my free Love Affirmations Mini-Course to help you to start thinking and feeling in a way that feels more like love. More resources and how you can start the process of Awakening(YourTrue)You and being the partner who creates your best version of what marriage looks like for you: https://christinebongiovanni.com/Join my AwakenYou newsletter for weekly marriage tips and early announcements of upcoming offerings.Book your free Courageous Love Conversation here.InstagramFacebook

What does it mean to live out of love rather than fear, and what difference does it make?

Sermon Title: How To Win A Losing Battle Yariana Abreu | COOL Church   COOL Church Online Sunday Services; Live at 9:30am & 11:30am | Sermon Streaming 7pm | Rebroadcast Tuesdays at 7:00pm Website: https://thecoolchurch.com Social Media (Instagram, Facebook, Twitter) @wearecoolchurch

Sermon Title: How To Win A Losing Battle Terrance Wilson | COOL Church   COOL Church Online Sunday Services; Live at 9:30am & 11:30am | Sermon Streaming 7pm | Rebroadcast Tuesdays at 7:00pm Website: https://thecoolchurch.com Social Media (Instagram, Facebook, Twitter) @wearecoolchurch

On this episode of Healthcare Americana, host Christopher Habig, CEO of Freedom Healthworks, is joined by Howard Berman, CEO of Coya Therapeutics. Together, they discuss the complexities of neurodegenerative diseases and the groundbreaking work being done to combat them. Explore the profound impact of conditions like ALS, Alzheimer's, and Parkinson's, and discover Coya's pioneering approach that utilizes Regulatory T-cells (Tregs) to revolutionize therapy for neurodegeneration. Howard offers insights into Coya's imminent breakthroughs, explains the critical role the immune system plays in all neurodegenerative diseases, and touches upon the process of working with the government to bring new treatments to the public. He also shares the tragic circumstance that occurred, which ultimately lead him to the overnight decision of leaving his career in big pharma and propelling him on this mission-based path. Finally, Howard concludes with the high expectations he has for Coya in the next 12 months. Don't miss this enlightening discussion that sheds light on the pressing need to address the growing epidemic of neurodegenerative diseases.Follow Healthcare Americana:TwitterInstagramLinkedInMore on Freedom Healthworks & FreedomDocMore on Howard Berman & Coya TherapeuticsSubscribe at https://healthcareamericana.com/episodes/

Hey Sox fans! Welcome back to Good Guys Talk Back. Nick and Pat weigh in on the Cleveland series and the Tim Anderson/Jose Ramirez 6th inning fist fight. It definitely sparked the team but it is something can help the Sox play better baseball? The Sox are 23 games under .500 have been continually plagued by the same issues all season long. Pedro Grifol is putting it on myself as to why things have not been done correctly over and over again. Is Pedro one and done? Although Pedro puts the blame on himself, shouldn't the players also be held accountable? Jake Burger was traded to Miami and Yoan Moncada still has back issues. Should Dylan Cease have been traded too? Rick Hahn believes the Sox can contend in 2024... contend for what? Thank you for the continued support, Go Sox. --- Send in a voice message: https://podcasters.spotify.com/pod/show/good-guys-talk-back/message

Truex Stays Ahead In War While Losing Battle, USWNT Should Be Criticized, Fast 5. Incl. LU Tragedy by Ed Lane

Co-founder Piers Curran returns to the Friday show to discuss:US interest rate expectations - Has the market gone too far, what does an inverted yield curve imply, and why a resilient economy is actually bad news for markets!UK mortgage crisis - Should you be worried?, how far north will interest rates rise and why the UK economic situation is the same but different from the USOPEC+ cut again - Russia joins Saudi Arabia in committing to supply cuts but are they fighting a losing battle?Free daily newsletter https://bit.ly/3Oeu4WkFree Finance Accelerator simulation https://bit.ly/3GoyV5rConnect with Anthony https://www.linkedin.com/in/anthonycheung10/Connect with Piers https://www.linkedin.com/in/pierscurran/ Hosted on Acast. See acast.com/privacy for more information.

We live in a culture where it's more common to be obese than fit. This leads to genrational obesity in families.Why is this?Is this a battle we can win?How much does it affect children?Will the next gernation going to outlive their parents?What leads to this?How can we change the course of gernerational obesity?

Today I am joined by Dr Jenny Linders from Skincheck Clinic in Bayside, Jenny, under the guidance of Dr Steve Karagiannis, a fellow of the skin cancer institute, who spends most of their time doing melanoma surveillance in their five clinics dotted around Dublin. I have spent a considerable amount of my time campaigning for more awareness in this arena, as it sometimes feels that despite applying copious amounts of SPF, skin cancer continues to be the fastest-growing cancer in the world. We, as an industry, need to do more. My team and I have gone into schools to educate the next generation of parents, and I have worked with VHI on a corporate level, raising awareness and educating people. This is the only way to soften the curve, in my opinion. A podcast episode dedicated to what more we can do is a natural next step. For more information on Skin Check or to make an appointment to see Jenny, Steve, and their team, heads to https://www.skincheck.ie/contact-us. Thank you so much to Jenny for giving up her time to be with us today, and please share this episode amongst friends and family, and together, we will make a positive change for our children.

Gwyneth, Kelly , Megan and Julia Fox, Beyonce and Me! A deep dive into every crazy diet we've ever tried (including parasites) and a solid human design strategy for you finding what will actually work for You

회화와 문법을 동시에 공부하는 Everyday English VOA 매일 영어 진행에 이은경입니다. 오늘은 결과가 뻔한, 질게 뻔한 싸움을 하다. 영어로 어떻게 표현하는지 살펴보겠습니다.

This episode is an exciting reunion with my high school art teach, Linda Barhydt! Back then, Linda had taught drawing and painting and now, she is teaching ceramics and creates beautiful pottery! And on this episode, we catch up on life, reminisce on the good ol' days, funny assignments, going from teaching how to draw and paint to ceramics, and so much more! —————————————————————— G's Nicknames for Linda 3:33 The Mannequin Drawings 5:17 D for Diploma 6:36 The Final Arts Assignment in High School 9:08 Linda's in Good Spirits as a Teacher 10:42 Teaching Ceramics During COVID 12:52 Teaching Young Students Today 14:46 Banning Phones in Class is a Losing Battle 20:08 Everybody Loves Raymond & Seinfeld 24:07 The A.I. Impact on English Teachers & Artists 25:36 The “G Time” Project 35:46 Making Lunch Money During Class 39:12 The RVA Journey 43:23 From Painting to Ceramics 54:43 Creative Growth & Natural Talents 1:02:10 The Process in Ceramics 1:09:08 Teaching How to Draw 1:12:44 Remembering Former Students 1:19:23 Talent & Hard Work 1:27:20 Linda Shares Some Inspirational Words 1:32:23 —————————————————————— For more G Terado —————————————————————— Follow on Instagram https://www.instagram.com/artofgterado/ Follow on Facebook https://www.facebook.com/ArtofGTerado Shop for Art https://theartofgterado.square.site —————————————————————— Thanks for tuning in!

This episode is an exciting reunion with my high school art teach, Linda Barhydt! Back then, Linda had taught drawing and painting and now, she is teaching ceramics and creates beautiful pottery! And on this episode, we catch up on life, reminisce on the good ol' days, funny assignments, going from teaching how to draw and paint to ceramics, and so much more! —————————————————————— G's Nicknames for Linda 3:33 The Mannequin Drawings 5:17 D for Diploma 6:36 The Final Arts Assignment in High School 9:08 Linda's in Good Spirits as a Teacher 10:42 Teaching Ceramics During COVID 12:52 Teaching Young Students Today 14:46 Banning Phones in Class is a Losing Battle 20:08 Everybody Loves Raymond & Seinfeld 24:07 The A.I. Impact on English Teachers & Artists 25:36 The “G Time” Project 35:46 Making Lunch Money During Class 39:12 The RVA Journey 43:23 From Painting to Ceramics 54:43 Creative Growth & Natural Talents 1:02:10 The Process in Ceramics 1:09:08 Teaching How to Draw 1:12:44 Remembering Former Students 1:19:23 Talent & Hard Work 1:27:20 Linda Shares Some Inspirational Words 1:32:23 —————————————————————— For more G Terado —————————————————————— Follow on Instagram https://www.instagram.com/artofgterado/ Follow on Facebook https://www.facebook.com/ArtofGTerado Shop for Art https://theartofgterado.square.site —————————————————————— Thanks for tuning in!

Congress high command doesn't look inclined to go for a change of guard in Rajasthan barely eight months before elections. Sachin Pilot finds himself in a catch-22 situation.

The problem is most people withdraw not by knowing but by feeling. To know is to apprehend fully. Apprehending fully the state of one's battle - if one is even truly in battle - and to discern if the state of war is not worth pursing takes a lot more time and effort and discernment than simply quitting based on my unreliable feelings and impulsive reacting. Why did the musician quit the band quietly and quickly? He simply didn't want to cause treble!

Brexit is done — insofar as it ever will be. But the Brexit we got was not the one most Britons wanted. Years of bad-tempered Parliamentary battling only came to an end when Boris Johnson purged his MPs and stopped the Commons from sitting, then called a general election. Ros Taylor is joined by Meg Russell and Lisa James, authors of The Parliamentary Battle over Brexit, to talk about the damage done, the legacy of those years — and whether we should ever have a referendum again.  “These terms of hard Brexit and soft Brexit only really come around after the referendum.” – Lisa James  “So much of the story of Brexit is what's going on with the Conservative Party over these years.” – Lisa James  www.patreon.com/bunkercast  Presented by Ros Taylor. Assistant Producer: Kasia Tomasiewicz. Music by Kenny Dickinson. Audio production: Jade Bailey. Lead Producer: Jacob Jarvis. Group Editor: Andrew Harrison. THE BUNKER is a Podmasters Production Learn more about your ad choices. Visit megaphone.fm/adchoices

We need to ask, “What is happening to our America?” If this has turned into Socialist Americans VS GOD WAR…then we are all in A LOSING BATTLE! Please stop whatever else you are doing and listen to the following words … Continue reading →

In this episode of the Myke and Joe PDR Show, our guests Graham (dent and detail pdr) and Martin (Dent Remover Beverly) will share their expertise on the Paintless Dent Repair (PDR) market in the UK. They will delve into the current pricing landscape, discuss how it differs from other regions, and examine the challenges posed by competition. Additionally, they will share their strategies for staying ahead in the market and achieving their business goals. Tune in for an insightful and engaging conversation on the UK PDR market. Martin - https://www.instagram.com/dent_remover_beverley/reels/ Graham - https://www.instagram.com/dentdetailpdr/reels/

Hola friends! Raise your hand if you feel like your busy schedule is kicking your heiny. Listen, I know what that's like to have one task or activity bleeding into the next…to have no downtime…no time to think…just go, go go. It's really tiring and overwhelming, not to mention, super stressful. It also contributes to those feelings of anxiety and defeat because, despite your best efforts, you just don't get everything done. If you've been asking the Lord to help get rid of the anxiety and just figure out how to make all this craziness stop, this episode is for you. Today, I'm going to shoot you straight and reveal the REAL reason you don't feel accomplished each day, even when you do everything “right.” Are you ready? Let's do it! Featured Review: Such a wonderful show! "Such a beautiful and powerful show! If you are a Christian woman, you need to listen. Her most recent episode about finding your verse of the year was super practical and encouraging."

I am in Agaro town in the Western coffee region near Jimma and Limmu. It feels like I am 70% in Ethiopia and 30% still back in Oakland. Despite jet lag, I talk about what I have learned so far about the competition for coffee cherry, and how the cooperatives are at a disadvantage when well-funded exporters open up coffee stations in the area. It's not all bad. Coffee farmers are selling cherry at high prices, which helps offset local inflation. I also added on some thoughts about Covid in Ethiopia and some interesting comments I heard from my Ethiopian.  This is part 1 of a series of recordings I made over morning coffee nearly every day on my December trip. They aren't perfect. They are monologues. They are a little embarrassing. But there are some good raw ideas in here, perhaps. I have 8-9 episodes if I can bear to post them all! It's a bit much.

Melissa and Jana engage in a real live conversation about a real life dilemma - Melissa's kids getting Gizmo watches.   As you know, Melissa is ANTI-Tech for kids in every way - to an unusually extreme level in Jana's opinion (and most people's actually). BUT, the father of Melissa's children would like to get the twins gizmo watches and Melissa is trying to balance the potentially reasonable request, her personal thoughts, and the complexity of handling this in a co-parenting relationship......with the help and wisdom of Jana who is slightly older than Melissa.  Enjoy this real conversation about a topic all parents have to deal with this day and age....when do kids get what tech.

Sometimes we feel like we're in a hopeless situation, that we're fighting a "losing battle." Today's message shares how God helps us win those seemingly unwinnable battles. We pray that it will encourage you as you fight your own daily battles.

On this episode we catch up on what I've been up to and we touch on fighting a losing battle and that is the battle against time. This is a short episode but I hope you enjoy it and if you do please share it thank you! --- Support this podcast: https://anchor.fm/theperfectmesspod/support

Enjoy --- Send in a voice message: https://anchor.fm/nursemandan/message

Joe Molloy was joined in studio by Dion Fanning and Bernard Jackman for this weekend's edition of the Sunday Paper Review. (00:00:38) A run through Sunday's back pages. (00:03:21) Wayne Rooney and his journey in football management. (00:24:41) Queen Elizabeth's passing and 'gesture politics' in sport. (00:35:00) David Beckham: A master at work. (00:43:38) Club rugby begins anew, farcical challenge posed by Emerging Ireland tour. (00:56:27) Why do all sports not face the same scrutiny when it comes to doping?

Joe Molloy was joined in studio by Dion Fanning and Bernard Jackman for this weekend's edition of the Sunday Paper Review. (00:00:38) A run through Sunday's back pages. (00:03:21) Wayne Rooney and his journey in football management. (00:24:41) Queen Elizabeth's passing and 'gesture politics' in sport. (00:35:00) David Beckham: A master at work. (00:43:38) Club rugby begins anew, farcical challenge posed by Emerging Ireland tour. (00:56:27) Why do all sports not face the same scrutiny when it comes to doping?

The Daily Shower Thoughts podcast is produced by Klassic Studios. Shower thoughts are sourced from reddit.com/r/showerthoughts Shower Thought credits: frencherfrench, RowBowBooty, TheSecondiDare, FutureSkeIeton, FictionVent, Island_Monkey86, T3knikal95, Tyrionus, WingSuspicious1203, TheRebelknight01, mako0804, coolbeanzswagdaddy69, malak_oz, Toomad316, That_Guy2847, Key_Ad_6455, PhoenixReboot-, deathlordfluffy, tsa_finest, MattOnePointO Learn more about your ad choices. Visit megaphone.fm/adchoices

With the midterms less than four months away, Republicans are lagging behind Democrats in grassroots fundraising: In the 10 most competitive Senate races, Democrats are out raising Republicans by more than $100 million with small dollar donors. Plus, police monitoring private surveillance video. And, the House votes to protect same-sex marriage. Guests: Axios' Lachlan Markay and Ina Fried Credits: Axios Today is produced by Niala Boodhoo, Sara Kehaulani Goo, Alexandra Botti, Nuria Marquez Martinez, Lydia McMullen-Laird, Alex Sugiura, and Ben O'Brien. Music is composed by Evan Viola. You can reach us at podcasts@axios.com. You can text questions, comments and story ideas to Niala as a text or voice memo to 202-918-4893. Go Deeper: GOP's grassroots money problem [draft--needs updating] House passes bill to codify marriage equality with large bipartisan support Learn more about your ad choices. Visit megaphone.fm/adchoices

7-2-2022

Fighting a losing battle - Need Prayer

This week, please join author Ronald Goldberg, Editorialist Hertzel Gerstein, and Guest Editor Rury Holman as we discuss the article "Effects of Long-term Metformin and Lifestyle Interventions on Cardiovascular Events in the Diabetes Prevention Program and Its Outcome Study" and the editorial "Shouldn't Preventing Type 2 Diabetes Also Prevent Its Long-Term Consequences?" Dr. Carolyn Lam: Welcome to Circulation on the Run, your weekly podcast summary and backstage pass to the journal and its editors. We're your co-host. I'm Dr. Carolyn Lam, Associate Editor from the National Heart Centre and Duke National University of Singapore. Dr. Greg Hundley: And I'm Dr. Greg Hundley, Associate Editor, Director of the Pauley Heart Center at VCU Health in Richmond, Virginia. Dr. Carolyn Lam: Today. Oh, this feature discussion involves the glance of diabetes. Truly this interview, I felt like I was sitting among gurus and just learning so much about diabetes, the history and the whole topic is about long term metformin and lifestyle interventions on cardiovascular events in the Diabetes Prevention Program and its outcome study. Now, way more than that, we discussed. You have to have to listen. But okay, before that, let's summarize today's issue for our listeners. Shall we, Greg? Dr. Greg Hundley: You bet Carolyn. So the first paper that I've got to discuss today really comes to us from the world of interventional cardiology and it's led by Dr. William Fearon from Stanford University Medical Center. Well, Carolyn previous studies have shown quality of life improves after coronary artery revascularization, more so after coronary artery bypass grafting than after PCI. Now this study aimed to evaluate the impact of fractional flow reserve guidance, and current generation zotarolimus drug-eluting stents on quality of life after PCI compared with CABG. Dr. Greg Hundley: Now the study emanates from fractional flow reserve versus angiography for multi vessel evaluation or the fame three trial. And Carolyn, that's a multicenter international trial that included 1500 patients with three vessel coronary artery disease who were randomly assigned to either CABG or FFR guided PCI. Now, what did they assess? So quality of life was measured using the European Quality of life Five Dimensions. And we're going to abbreviate that EQ-5D questionnaire baseline, one, and then 12 months following the procedure. Also, Canadian cardiovascular class angina grade and working status were assessed at the same time points, and then also an additional time point in six months. And the primary objective was to compare the EQ-5D summary index at 12 months, and secondary endpoints included angina grade and work status. Dr. Carolyn Lam: Ooh, interesting Greg. So quality of life in the theme three trial. All right. So what did they find? Dr. Greg Hundley: Right, Carolyn. So the EQ-5D, so that... European Quality of life Five Dimensions summary index at 12 months did not differ between the PCI and CABG groups, but the trajectory over the 12 months at the one month time interval between PCI and CABG did differ. Now, the proportion of patients with the Canadian cardiovascular class or CCS2 or greater angina 12 months was 6.2% versus 3.1% respectively in the PCI group compared with the CABG group. Additionally, a greater percentage of younger patients, so those less than 65 years old were working at 12 months in the PCI group compared with the CABG group. So in summary, Carolyn, in the fame three trial, quality of life after fractional flow reserve guided PCI with current generation DS compared with CABG was similar in one year. And the rate of significant angina was low in both groups and not significantly different. However, the trajectory of improvement in quality of life was significantly better with PCI as was working status in those less than 65 years old. Dr. Carolyn Lam: Wow. Thanks Greg. Hey, guess what? It's time for Greg quiz. The next paper is about the Chocolate Touch Study. So, Greg, is this about, A, the benefits of eating chocolate? B, the benefits of chocolate mud baths? Or C, the benefits of a second generation drug coated balloon? Dr. Greg Hundley: So, Carolyn, I just have one question. Where in the world do we get the benefits of chocolate mud bath? I don't think that's right. I do love eating chocolate, but I am going to go with the benefits of the second generation drug coated balloon. Dr. Carolyn Lam: Yeah, yeah, yeah. I made it easy for you. All right. So first generation drug coated balloons have significantly reduced the rate of restenosis compared to balloon angioplasty alone. However, high rates of bailout stenting and dissections persist. The chocolate touch drug coated balloon is a nitinol constrained balloon designed to reduce acute vessel trauma and inhibit neointima formation and restenosis, so you were right, Greg. In today's study led by Dr. Shishehbor, from University Hospital's Harrington Heart and Vascular Institute at Cleveland, Ohio. They studied 313 patients with claudication or ischemic rest pain, and superficial femoral or popliteal disease. And randomized them one to one to the chocolate touch or Lutonix Drug Coated Balloon at 34 sites in the United States, Europe and New Zealand. The primary efficacy endpoint was drug coated balloon success defined as primary patency at 12 months. The primary safety endpoint was freedom from major adverse events at 12 months. A composite of target limb related death, major amputations, or reintervention. Both primary endpoints was assessed for non-inferiority and have met sequential superiority testing for efficacy was pre-specified. Dr. Greg Hundley: Interesting, Carolyn. So this nitinol constrained balloon designed to reduce acute vessel trauma. So, what were the results of this study? Dr. Carolyn Lam: So in this trial, the second generation chocolate touch drug coated balloon met both non-inferiority endpoints for efficacy and safety. And was more effective than the Lutonix Drug Coated Balloon at 12 months for the treatment of femoral popliteal disease. Cool, huh? Dr. Greg Hundley: Very interesting. Great summary, Carolyn. So Carolyn, my next paper comes to us from the world of preclinical science. And the impact of three dimensional chromatin topology on transcriptional dysregulation and pathogenesis in human dilated cardiomyopathy remains elusive. And so these authors led by Professor Lei Jiang from Guangdong Provincial People's Hospital, and Guangdong Academy of Medical Science, generated a compendium of 3D epigenome and transcriptome maps from 101 biobank human dilated cardiomyopathy, and non-filing heart tissues and mouse models to further interrogate the key transcription factor implicated in 3D chromatin organization, and transcriptional regulation in dilated cardiomyopathy pathogenesis. Dr. Carolyn Lam: Oh, wow. Sounds like a lot of work. What did they find, Greg? Dr. Greg Hundley: Right, Carolyn. So they found that enhancer promoter connectomes are extensively rewired in human dilated cardiomyopathy, which reside in pre accessible chromatin size and also hand one drives the rewiring of enhancer promoter connectome to induce dilated cardiomyopathy pathogenesis. Dr. Carolyn Lam: Okay, Greg. So what are the clinical implications? Dr. Greg Hundley: Right, Carolyn. So first, dilated cardiomyopathy enriched enhancer promoter loops identified in this study could be developed as novel 3D genomic biomarkers for dilated cardiomyopathy. And then second Carolyn, targeting hand one might be used as a novel approach for therapeutic intervention in patients with dilated cardiomyopathy. Dr. Carolyn Lam: Oh, nice. Greg. Well, also in today's issue, there's an On My Mind paper by Dr. Brook, entitled, “The Doctor is Out, New Tactics and Soldiers For our Losing Battle against Hypertension.” In another paper, we have Molly Klemarczyk bringing us highlights from the Circulation Family of Journals. Dr. Greg Hundley: Right, Carolyn. And also from the mailbag, there's a Research Letter from Professor Baggish, entitled, “Cardiovascular Outcomes in Collegiate Athletes, Following SARS-CoV-2 Infection: The 1-Year Follow Up From the Outcomes Registry for Cardiac Condition in Athletes.” Well, Carolyn, how about now we get onto that feature discussion and learn a little bit more about the long term metformin and lifestyle interventions on cardiovascular events in the Diabetes Prevention Program. Dr. Carolyn Lam: Hold on to your seats, everyone. Here we go. We know that lifestyle intervention and metformin have been shown to prevent diabetes. However, what is their efficacy in preventing the cardiovascular disease associated with diabetes development? Well, guess what? We're going to have data on that through today's feature paper and what a star crowd I'm talking to today. We have Dr. Ron Goldberg and he's a first end corresponding author from the University of Miami Diabetes Research Institute. We have the editorialist Dr. Hertzel Gerstein from McMaster University Population Health Research Institute. And a guest editor for this paper, Dr. Rury Holman from University of Oxford. I have to admit I'm starstruck. You gentlemen have totally defined the field. I cannot wait to learn more, but shall we start with you, Dr. Goldberg? Could you tell us a little bit more about your paper, what you did, what'd you found? Dr. Ronald Goldberg: So the background is that the Diabetes Prevention Program started in 1996 was a Diabetes Prevention Program to test the effects of intensive lifestyle intervention versus metformin, versus placebo on the prevention of diabetes in over 3000 individuals with impaired glucose tolerance, a form of prediabetes. And after demonstrating the efficacy of those interventions over about three years, we went on to do a follow up study in which the metformin group continued to receive it. Everybody got lifestyle because it worked so effectively. And we are now reporting after a further 18 years of follow up on the question of whether these interventions, now 21 years later, had any effect on cardiovascular outcomes. The background to that of course, is that people with prediabetes have a somewhat increased risk for heart disease and that rate increases as diabetes develops, particularly with severity of hyperglycemia and duration of diabetes. So, that was the study and we're now reporting on whether these interventions had a significant effect on the major cardiovascular. Dr. Carolyn Lam: Well, first Dr. Goldberg, congratulations on the foresight to get the informed consent and to plan ahead to be able to get these valuable data. But because I know this is going to be a critical point later. Could you tell us a little bit about the completeness of follow up and perhaps surveillance for outcomes before you share the results? Dr. Ronald Goldberg: Absolutely. So, 86% of the original randomized group of participants agreed to continue with a follow up study, so there was a loss at that point. And then of course, over 18 years of follow up, there's going to be a further loss. Some due to death and some due to loss to follow up. But despite that, I would say the group that entered the follow up study, we were able to maintain follow up in 85%. Dr. Carolyn Lam: Fantastic. And the results? Dr. Ronald Goldberg: The findings were that we found no significant effect of either of the two active interventions on our primary cardiovascular outcome, which was nonfatal myocardial infarction, stroke and fatal cardiovascular disease. We also had an extended outcome with more events in it, and similarly found no significant benefit or harm from either of those two intervention. Dr. Carolyn Lam: Oh, I love that paper. What a great, great, perhaps surprising conclusion that Dr. Gerstein loved the title of your editorial, you crystallize it. Shouldn't preventing type two diabetes also prevent long term consequences? So please tell us what was your thoughts when you saw this paper and how you frame it? Dr. Hertzel Gerstein: Thanks very much, Carolyn. And first of all, I was very impressed by the extensive amount of work and analysis done by Dr. Goldberg and his team. I thought that it's wonderful to see this sort of long term follow up. I've had the privilege in the past of speaking together with the DPP team on their trial and in their long term follow up. And I continue to be impressed by the extensive amounts of work and data collected and a rigor and academic value of the analysis. So, that was my very first impression and obviously it's a pleasure to write on this. I think the findings are clearly important and they both highlight the importance of long-term follow up as well as highlight the difficulties of long-term follow up in a study like this. Dr. Hertzel Gerstein: So this was a study done in a trial, originally done in a fairly young cohort of individuals who had very low risk for cardiovascular events. And over their 18 year follow up that Dr. Goldberg Ron described, the actual annual event rate for the primary outcome was 0.6% per year in that ballpark. Now, anybody... I've had the privilege as Ron Avery of doing many cardiovascular trials and we all know that we would never start a trial recruiting people with an event rate of 0.5% per year, 0.6% per year, because we would have to recruit 30,000 people and follow them for seven years in order to accrue enough events to be able to detect a clinically relevant benefit of the therapy. So because of this low event rate, the advantage was the long term follow up, the 26th year, I think it was in the end follow up. No, it was a 21 year median follow up period, because of the long follow up, you get a little bit away from the advantage of the low event rate. Dr. Hertzel Gerstein: But even then, over the course of the 21 years, there were only about 310 first cardiovascular events and most cardiovascular outcomes trials, for instance, we need close to at least a 1000, 500 to a 1000 is what we like to see. So that being said, it's perhaps not surprising that we didn't see a benefit of diabetes prevention because even if diabetes reduces the risk of a cardiovascular event by a quarter, by 25%, there would've only been a 50, 50 chance of detecting that with this particular cohort of people. Dr. Hertzel Gerstein: So I would say that the most conservative assumption is that diabetes prevention doesn't reduce the event rate by 25% or less or 30, but it's certainly... pardon me, by 25% or more, it could reduce it by 20%, 15% we would not have detected at all, or Ron would not have detected and his team would not have detected it with this thing. So I think that to me is the most important caveat in interpreting this does not mean that diabetes prevention has no effect on cardiovascular outcomes. Dr. Hertzel Gerstein: It means that diabetes prevention doesn't have a moderate or smaller effect. So, that's I think the most important message to take and as is even mentioned in the paper by Ron and the team is that there has been at least one diabetes prevention trial conducted in China many, many years ago that showed clearly that people who were randomly assigned to the diabetes prevention arm, 26 years later did have lower cardiovascular events and even death than people who were in the control arm. So, I think this adds to the story but it's clearly like everything, not the final word in this, but it certainly adds a lot of important data. Dr. Carolyn Lam: Oh, I would love to hear Dr. Goldberg's response to that. But before that, Dr. Holman, could I ask you to weigh in as well? Dr. Rury Holman: Yes. Sure. So, I agree with Hertzel that this is underpowered, but this is a question I've long wanted to see the answer to. And I congratulate Ron and his team for actually doing the work. All major studies should have long term follow up. People should be consented for life so that we can answer these questions. And Hertzel even though the power is perhaps minimal, we still need to do this analysis. Dr. Rury Holman: And if there had been a dramatic result, then we'd have all been very excited. I think one of the issues... one, if I could just bring it up, you mentioned the look ahead study in your discussion as being a negative dietary intervention. But I have a slightly different take on that. When you look at that paper in detail, what you see is that the people in the usual care group forgot quite a lot more risk factor reduction medications, and that's because their usual care physicians spotted the fact that their risk factor levels were higher than in the intensive care group, of course it was blinded at that point. But there's a whole point here is, in your paper you show an increase in the statin proportion, which is higher in the placebo group compared with the metformin and your intensive lifestyle, significantly so for the lifestyle one. So I'm just wondering whether even the low power was further blunted by the drop in effects of these other medications. Dr. Ronald Goldberg: Thanks very much for those comments guys, I think they're spot on. Let me first respond Hertzel with my thoughts on this, and then go over to your point, Rury. I think it's really interesting to look back over time and realize how much medical management has changed. And that goes right to your point, Rury, that doing a clinical trial like this where the primary care physicians are informed about what we're doing, what... communicated with on a regular basis, particularly when their patients develop diabetes, it just heightens the entire level of medical management. And I think you're absolutely right, but it's interesting to see what's happened to cardiovascular disease over the last 25 years, both in the general population and in the prediabetic population, the risk of cardiovascular disease has gone down. And then on top of that, we've got this very intensive cardio prevention intervention by primary care physicians, with high rates of statin usage, high rates of any hypertensive treatment, even the placebo group to your question, really lost weight. Dr. Ronald Goldberg: And they knew full well what was... and this was a very hands on type of study where our participants were really followed now for all these years, really became integrated with the research team. And so everybody knew what everybody else was doing. And so I'm sure the placebo effect was very strong, but I think nevertheless... Oh, and the last point I wanted to make was of course, the severity of the diabetes, even though 60% are developed diabetes, the severity of the diabetes was relatively mild. Even in those who developed diabetes, we know their average A1C was only about 6.7. And so I think that has a lot to do with blunting the acceleration effect of diabetes on cardiovascular disease. So, I think all of these factors contributed together to produce a negative result. But I think an important message, nevertheless. Dr. Hertzel Gerstein: I can highlight that point, that Ron was saying is that if diabetes prevention is going to prevent cardiovascular outcomes, it's going to do that because of a difference in glycemic exposure. The diabetes is by definition a disease of an elevated blood sugar. So if diabetes prevention prevents cardio, it means that the blood sugar's going to be lower than it would otherwise be. So if there's very little difference over the long term follow up in blood sugar because of co-intervention and therapy of all the treatment groups, then that would eliminate a lot of the benefits of diabetes prevention, because these are patients who are in this trial, who are being scrutinized even more than they would be if they were out there free range without being involved in any follow up. So, that's a spot on point. Rury, you wanted to comment. Dr. Rury Holman: Yeah. So, Hertzel just to expand on that. Obviously the glycemic impact on macrovascular disease is relatively modest compared to the impact on microvascular disease, which of course is what we all saw originally with type 2 diabetes. In fact, in KPDS35, when we looked or calculated what 1% reduction in A1C would do, it would only reduce stroke or MI by about 12 to 14%. So it's quite a shallow slope if you like. And your point is spot on is if that glucose levels are kept low by good treatment and good management role tell us about the great team they have. Then there was no room for a glycemic impact in this particular study. It's another question, whether you think metformin acts by different mechanisms to reduce cardiovascular disease, that's another question I had for Ron that he might like to address, is if there was a magic effect of metformin, why didn't we see that? Dr. Ronald Goldberg: And that's a really interesting question, Rury, because you may be aware that we published a paper a few years ago on our assessment of coronary calcification in a subgroup, in about 60% of the population who agreed to do this and who were eligible. And interestingly found that metformin did was accompanied by a reduction in the prevalence of coronary calcium in men, not women. Dr. Ron Goldberg: And the effect was actually when we did subgroup analysis, we found it was particularly strong in young men. And actually that gave us some sense of optimism that we might see something when we came to actual events. And of course, as you all know, metformin has beneficial effects on several cardiovascular risk factors. And so the question is whether there is some effect of metformin that might yet be identified, a coronary calcium after all is a surrogate of events and may take time, or it may be that... And we are really interested in the idea that both prediabetes and diabetes are heterogeneous. There's more and more interest in looking at subgroups of individuals who may be more predisposed. And it may be that metformin might have beneficial effects in some of those subgroups. Dr. Hertzel Gerstein: But also remember on the other hand, there was a lot of co-intervention with metformin in all groups after the trial was over. So all groups were offered metformin, et cetera. So even if metformin had an effect, it could have easily been washed out by the exposure of all the other groups to metformin during follow up. But Ron, you also touched on both the hope and the frustration too, because if we start thinking about subgroups, we can always think of subgroups. Yeah. But then the problem with subgroups is you have a study, let's say you have a cohort study with 7,000 or 10,000 people and it followed for five years and, oh, well the effect isn't in all 10,000, it's only in 20% of them. So now you have a study of 2000 people, that's not enough to detect an effect in a subgroup. Dr. Hertzel Gerstein: So, subgroups just eat away at power in an exponential, not a linear way, so that you just rapidly lose any ability to detect anything. And so, yes, this is going to work in people with these three snips on this gene, in this subpopulation. Good luck, that's the difficulty and the challenge of... We need to find sometimes better or more efficient ways of identifying outcome protective therapies, because we can't keep drilling into some groups because we just don't have the resources to find it really. I don't know what other people feel about that, but. Dr. Carolyn Lam: I'm personally so enjoying this conversation as I know the audience is and we covered a lot. I'm sure everyone wants to pick up the paper and the editorial. Now, we talked about being underpowered for the number of studies. We talked about profitable dilution of things like statins, antihypertensive agents, even the crossover of potential treatment in the placebo arm and so on. And then we started talking about, or is it the how you got there and the drug that was used. And here, please don't shoot me, but I just know I have the answers on behalf of everyone else's thinking it. What do you say of people who go, "Well, it's because it's metformin. What if it was an SGLT2 inhibitor? What if it was a GLP-1 receptor agonist?" And as you know, a lot of people say those would in spite of the effect on glucose. Dr. Hertzel Gerstein: I can quickly jump in. It's very clear. We've learned this in the last 10 years, is that there are glucose lowering drugs and there are glucose lowering drugs with benefits. And the GLP-1 receptor agonist and the SGLT2 inhibitors are glucose lowering drugs with benefits. They lower glucose, but they seem to have a separate cardioprotective effect. And with the SGLT2 inhibitors that cardioprotective effect does not seem to be related to the glucose lowering. There are a few meta regression analyses that suggest that with the GLP-1 receptor agonist, part of the cardioprotective effect is related to glucose lowering and part is not. And clearly mediation analysis with some of the trials have shown the same thing with the GLP-1 receptor agonist, not really with the SGLT2 inhibitors. So, maybe, that's my spin on this. Dr. Carolyn Lam: Dr. Holman. Dr. Rury Holman: Yeah. I was going to echo what Hertzel said in that regard, these other agents do have multiple effects. They change weight, they change blood pressure. And so other risk factors are brought into play other than glucose lowerings. We've already agreed, glucose lowering impact on cardiovascular disease is quite modest. I'd rather have it than not, but it wouldn't be my primary way to treat cardiovascular disease. And coming back to Ron's study, which is crucial today, the issue here is whether we could untangle an impact particularly of metformin, which has been foundation drug for type 2 diabetes for so long. Dr. Rury Holman: But clearly within the dataset we have here, underpowered it is. There are no clear messages in that respect, which is disappointing, but it doesn't mean that there isn't an effect. With longer follow up, with more data than you might see it. When the study... I'm coming for you Hertzel, was stopped for futility then the hazard ratio has changed, that often the way, not for the right way, but it's often what happens when you stop studies. I wondered if you wanted to comment on that aspect, because I know it's something that you've talked a lot about. Dr. Carolyn Lam: Dr. Gerstein. Did you want to? Dr. Hertzel Gerstein: I agree with what Rury said. I think the point you're making Rury goes back to power, and the ability to have enough people and enough events to detect and effect and that's clearly true, so... Dr. Carolyn Lam: Well, I hate to be the one to break the party up, but we have gone over time and intentionally so, there's just so much learning here. But Dr. Goldberg, could I give you the last say please? What do you think is the important clinical take home message of your paper? Dr. Ron Goldberg: Well, I think that the fact that we demonstrated that our study has been able to maintain really low levels of cardiovascular risk factors, low levels of A1C, even though that likely contributed to the negative finding still leaves the physician where the recognition that it is important to identify individuals with prediabetes to Institute Diabetes Prevention Programs, because I think it's entirely possible as I said earlier, and we've begun to identify them, subgroups of individuals who do progress more rapidly and who do warrant a more effective treatment, which would come from an early intervention program. Dr. Carolyn Lam: Wow. Thank you so, so much for that. Thank you so much. All three gentlemen for this amazing discussion. Well, audience, you heard it right here on Circulation on the Run from Greg and I thank you for joining us today and don't forget to tune in again next week. Speaker 6: This program is copyright of the American Heart Association, 2022. The opinions expressed by speakers in this podcast are their own and not necessarily those of the editors or of the American Heart Association. For more, please visit ahajournals.org.

Reality .v.s. Fantasy logic .v.s. Emotion will the women of this world really understand men

* Guest: Bryan Rust - Over the past 50 years, Rust Coins has been working to educate customers about precious metals - RustCoinAndGift.com * Bryan Rust AKA Dr. Honest Money! * Honest Money Report: Gold: $1960.20 Silver: $25.40. * Growing Number of Experts Call on US Government to Recognize Natural Immunity - CDC vaccination schedule should incorporate prior infection, experts say - TheEpochTimes.com * The Losing Battle to Fix Gold at $35 - Mises Institute. * Feds, Yellen Advance New Policies to Eliminate Paper Money - WND.com * Cashless Society: US Democrats Propose 'Digital Dollar. * Democrats Pushing Cashless Currency Legislation. Forbes Report: China's Digital Money to be Ultimate Financial Censorship Tool. * How can we Fight Against A "Cashless Society"? * I care not who controls a nation's political affairs so long as I control her currency - Mayer Amschel Rothschild. * Chinese State Media Accidentally Releases Censorship Rules on Russia–Ukraine Coverage - TheEpochTimes.com * Glenn Beck argues that the American way of life will not survive the Great Reset and warns us to stop it before it's too late to reverse course.

The Break Room (2/8/22) 7am Hour Includes: 1) We have ALL done this after a bad break up, right? 2) The plow VS my expensive mailbox. 3) Is this Olympic sport even that hard?

A South African soldier has been killed in an ambush in Mozambique. Security analyst Jasmine Opperman says the false narrative being created by SADC leaders that the war in Mozambique is a false one that could sadly cost more South African lives on the frontline. See omnystudio.com/listener for privacy information.

1 Samuel 19:19-24

Yemen's civil war rages on. Unless the United States can come to terms with its poor strategic and moral position, things will only get worse. -Important References- https://www.spectacles.news/focus-the-dangers-of-an-existential-struggle (On the global competition between democracy and autocracy) -Usual Links- https://www.spectacles.news/insight-normalcy-an-inadequate-solution-in-a-changing-world/#/portal/ (Visit our website and subscribe to our newsletter!) https://www.spectacles.news/a-losing-battle-with-no-winners-insight/ (To read or comment on this article, click here.) https://spectacles-birds-eye.captivate.fm/listen (To listen to a discussion of this episode from Spectacles In Conversation, click here.) https://twitter.com/SpectaclesMedia (Follow us on Twitter!)

Ep.4 In honor of breast cancer awareness month Robbie tells her story watching her mom fight breast cancer and the effects it had on her and everyone around her. --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app Support this podcast: https://anchor.fm/keyla-mcdaniels/support

"Fighting a Losing Battle" with Vernon Sims Recording of the 10/11/2020 livestream of the CONNECT Online Bible Study. CONNECT is sponsored by Digital Bible Study and is an interactive video and audio livestream every Monday, Tuesday, Thursday, and Friday evenings at 7:00 PM ET. The podcast version is uploaded the next day. You can find the livestream on all of social media platforms: Facebook: https://www.facebook.com/digitalbiblestudy1 YouTube: https://www.youtube.com/channel/UC_oFtSAY5QESpBu6IDp_tvA Rumble: https://www.rumble.com/user/digitalbiblestudy Podbean: https://digitalbiblestudy.podbean.com/   Follow Us: Subscribe at: https://www.digitalbiblestudy.org Merch: https://shop.digitalbiblestudy.org

In today's episode I am joined by my friend, author and host of the Kingdom Mamas Podcast, Trudy Lonesky, to take on a very important lie the enemy speaks to the hearts of Moms. The lie is: I'm Fighting A Losing Battle - the world's influence is greater than mine - and here's why we are discussing this topic today... The enemy's pursuit of the misleading and destruction of our children, I believe, is worse than ever before. With countless outside influences speaking conflicting messages into their hearts and minds, how can Christian Moms stay ahead of the game and maintain godly influence over their children's lives? Take heart, Mama, you are bolder, stronger and more capable than you can possibly imagine and today, Trudy and I want to encourage and empower you to take on the enemy with a battle plan straight from God's Word. You can connect with Trudy on Instagram and Facebook and be sure to listen to the Kingdom Mamas podcast! You can connect with Somer on Instagram and Facebook - and be sure to download this week's Lies Good Moms Believe Prayer Guide HERE! Favorite Takeaways and Scriptures Referenced in today's episode: Ephesians 6:12 Whatever is precious to God is precious to the enemy The enemy wants nothing more than to take the identities of our children and to lie to them on the daily and to turn them away from God because, let's face it, we are raising the next generation of disciples. So we have to stand firm and rebuke these lies. The enemy wants nothing more than to disconnect the family unit and that foundation that we are creating in our children to create Christ followers. John 10:10 He wants nothing more than to keep our children from spreading the gospel and being a light in this dark world He wants this world to be dark and noisy and he wants it to be confusing for them Operate in an Ephesians 6 mindset If we stand as a victim, we are not actively creating “God-fidence” = God confidence Are we looking for worldly valuation or are we looking to scripture? Our thought life is powerful Phillipians 4:8 Is it true, noble, kind, praiseworthy? If it's not, it's not of God and it has to go. Let's take a step back from what's being said to you - if' its not, it's not God breathed. Let's disconnect from that and let's hold on to Truth. God says I'm chosen, God says I'm set apart, God says that He has plans and a future for me. Romans 12:2 - Do not conform to the patterns of this world, but be transformed by the renewing of your mind It's time to stand out through the way that we live our lives. Bark technology Pinwheel phone We are spiritual guardians over our children from the time they are entrusted to us Declarations of prayer over your child: This child is covered by the blood of Christ The plans of the enemy will not prosper against this child I will loose and bind any spirit that comes against this child This soul must be so precious because both God and the enemy are after it The Word is our weapon Jesus countered everything the enemy said with God's Word Psalm 91 - insert your child's name in that passage Proverbs 3:5-6 Jeremiah 29:11 The Blessing - by Kari Jobe You Version Bible App  Audible

SIGN UP FOR THE POTTER DISCUSSION NEWSLETTER AND CLAIM YOUR GUIDE HERE!In this episode I explain why Quirrell could never actually get past Fluffy. Enjoy!Summary:  Quirrell was the first in the long line of defense against the dark arts teachers. It turned out he was a double agent working with Voldemort to steal the sorcerer's stone. He was an inch away from success when Harry showed up and defeated him. However, I think there was a unique wreck in his plans that really sent the train off the rails. Fluffy the three headed dog is immortal. This is as far fetched as it goes. To start, I don't even think Quirrell  could have gathered enough strength to cast the killing curse in the first place. You need to be very powerful to do so. Even at his best Quirrell might manage, but carrying Voldemort around in the back of his head really sapped his strength. But Fluffy is immortal so it wouldn't matter anyway. Here's why I think Fluffy is immortal. For one, we never see him as a puppy. With Norberta, we saw her right from the start of her life. Not Fluffy. Here's where it gets good. There is another giant three headed dog. His name is Cerberus. Cerberus is the three headed dog from Greek mythology that guards the underworld. One of the most used entries to the underworld is in Greece. You know where Fluffy is from? Greece. Hagrid has said himself that Fluffy is one of kind. That may true. Could it be because Fluffy and Cerberus were the same thing all along?Gmail: ThePotterDiscussion@Gmail.comInstagram: @thepotterdiscussionWebsite: https://www.thepotterdiscussion.buzzsprout.com

The media/big tech can only conceal the massive, coordinated election fraud for so long until they can hide the truth no longer. And the centerpiece for constitutional, election integrity is the lawsuit filed by Texas – and joined by many other red states – to prevent Georgia, Michigan, Pennsylvania and Wisconsin from certifying their 2020 election results because those states violated Article II, Section 1 and the 14th Amendment. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.